In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

The recent bankruptcy of genetic testing firm 23andMe has raised alarms for privacy advocates and consumers worried about ...

The direct-to-consumer (DTC) genetic testing market is projected to grow at a CAGR of ~12% over the forecast period. Major ...

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to ...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics ...

KLP Kapitalforvaltning AS acquired a new position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The ...

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian ...

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics ...

These tests help spot any problems that could affect them, such as birth defects or genetic diseases. The results can help you make the best health care decisions before and after your child is born.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel ...

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned a consensus rating of “Hold” from the fifteen research firms that are currently covering the firm, Marketbeat reports. Three ...

Shares in genetic testing firm 23andMe dropped Monday after the company declared bankruptcy and California reminded consumers of their right to have their data deleted. March 24, 2025 Once a ...